Sanofi reported that its bispecific antibody drug lunsekimig (targeting TSLP and IL-13) doubled phase 2 respiratory wins while failing to improve atopic dermatitis severity in a separate phase 2 study. In the phase 2b Aircules asthma trial, the program met its primary endpoint by reducing exacerbations over 48 weeks. In chronic rhinosinusitis, lunsekimig achieved the phase 2a Duet primary goal of reducing nasal polyps over 24 weeks. However, in the phase 2b Velvet atopic dermatitis study, Sanofi said the drug missed the primary mission to reduce eczema severity, though it noted improvements on some secondary endpoints. The company framed the dataset as supportive of lunsekimig’s dual-target mechanism and said safety was generally consistent across the respiratory trials, with plans to hold certain details for upcoming medical congresses.